Medical cannabis combination business plant canopy increase to cultivate cannabis sold as medical cannabis flower or medical cannabinoid products provision
Manufacture of certain products for sale outside of Minnesota provided, tetrahydrocannabivarin designated as a nonintoxicating cannabinoid, potency limits modified, social equity ownership requirements lowered to 51 percent, manufacturing limits established, and cannabis cultivator license authorizations clarified.
Plant canopy that a medical cannabis combination business may use to cultivate cannabis that will be sold as medical cannabis flower or medical cannabinoid products increased.
Office of Cannabis Management required to establish limits on the total THC in cannabis flower and cannabis products; addition of ingredients to impart a taste or smell to cannabis products intended to be consumed through the inhalation of smoke, vapor, or aerosol prohibited; warnings about cannabis consumption required to include a warning regarding cancer; and advertisements prohibited that promote the co-consumption of alcohol and cannabis.
Payment rates established for certain substance use disorder treatment services, and vendor eligibility recodified for payments from the behavioral health fund.